We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Please provide feedback for this on the following(scale 1-5, 1 strongly disagree; 5 strongly agree):
* = Mandatory Field
New journal coming to touchIMMUNOLOGY soon!
touchREVIEWS in RMD. 2023;2(1):46–49 DOI: https://doi.org/10.17925/RMD.2023.2.1.46
Biologics are medications derived from biological sources used to treat several immune-mediated inflammatory diseases. These medications interfere with autoimmune processes by inhibiting specific molecular or cellular targets. They are highly effective medications, mostly used in cases of moderate-to-severe disease activity. As such, biologics have revolutionized the treatment of and transformed outcomes for patients with rheumatological […]
touchREVIEWS in RMD. 2023;2(1):42–45 DOI: https://doi.org/10.17925/RMD.2023.2.1.42
The preamble of the World Health Organization’s constitution defines health as “a state of complete physical, mental and social wellbeing, and not merely the absence of disease or infirmity”.1 An optimal state of health is considered a fundamental human right. When each human has the ability and opportunity to attain optimal health, only then can a […]
touchREVIEWS in RMD. 2023;2(1):28–36 DOI: https://doi.org/10.17925/RMD.2023.2.1.28
Systemic rheumatic diseases (RDs) commonly arise during a woman’s reproductive years and may have implications for family planning and pregnancy. Among the RDs, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are classically associated with an increased risk of adverse pregnancy outcomes (APOs), including miscarriage, foetal loss, preeclampsia, intrauterine growth restriction (IUGR) and preterm delivery.1–4 Although SLE pregnancy outcomes have improved over time, maternal mortality remains higher in women […]
Get the latest clinical insights from touchIMMUNOLOGY